stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Free cash flow
Alnylam Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was $465.4M, compared with −$42.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $806.3M. Over the past ten years it has ranged from −$718.1M (fiscal 2021) to $465.4M (fiscal 2025) — the current reading is the highest in ten years. Alnylam Pharmaceuticals, Inc. ranks 8th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $465.4M | — |
| FY2024 | −$42.6M | — |
| FY2023 | $41.9M | — |
| FY2022 | −$613.3M | — |
| FY2021 | −$718.1M | — |
| FY2020 | −$685.3M | — |
| FY2019 | −$418.6M | — |
| FY2018 | −$689.5M | — |
| FY2017 | −$487.0M | — |
| FY2016 | −$372.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $271.2M | (7.15%) |
| Jun 2026 | $292.0M | 500.04% |
| Mar 2026 | $48.7M | (74.97%) |
| Dec 2025 | $194.4M | (31.71%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. | $806.3M |
| INCY Incyte Corporation compare | $679.9M |
| JAZZ Jazz Pharmaceuticals PLC compare | $664.5M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.8M |
| BNTX BioNTech SE Sponsored ADR compare | −$524.1M |
| INSM Insmed, Inc. compare | −$627.6M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement